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Atherosclerosis is a chronic disease with features of inflammation across the distinct stages of development.1 
Plaque rupture and erosion with ensuing thrombus formation 
and occlusion of the artery lead to acute clinical complica-
tions comprising acute coronary syndrome (ACS),2 which 
constitutes one of the leading causes of death worldwide.3 
Therefore, there is a great medical need to improve risk pre-
diction in asymptomatic patients,4 to improve early diagnosis 
and risk stratification of patients with ACS5 and to monitor 
atherosclerotic burden during treatment.
Proteins that are secreted or released from atherosclerotic 
lesions or thrombi into the circulation may provide a direct 
and simple measure of the atherosclerotic burden in individual 
patients. This concept has already been examined in the diag-
nosis and monitoring of other diseases, for example, several 
types of cancers by tumor markers.6
For the discovery of such biomarker candidates, we com-
bined gene expression profiling of coronary thrombi versus 
peripheral blood mononuclear cells and proteomic analysis 
of secretomes derived from atherosclerotic plaques versus 
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Objective—Blood-borne biomarkers reflecting atherosclerotic plaque burden have great potential to improve clinical 
management of atherosclerotic coronary artery disease and acute coronary syndrome (ACS).
Approach and Results—Using data integration from gene expression profiling of coronary thrombi versus peripheral blood 
mononuclear cells and proteomic analysis of atherosclerotic plaque–derived secretomes versus healthy tissue secretomes, 
we identified fatty acid–binding protein 4 (FABP4) as a biomarker candidate for coronary artery disease. Its diagnostic 
and prognostic performance was validated in 3 different clinical settings: (1) in a cross-sectional cohort of patients with 
stable coronary artery disease, ACS, and healthy individuals (n=820), (2) in a nested case–control cohort of patients 
with ACS with 30-day follow-up (n=200), and (3) in a population-based nested case–control cohort of asymptomatic 
individuals with 5-year follow-up (n=414). Circulating FABP4 was marginally higher in patients with ST-segment–
elevation myocardial infarction (24.9 ng/mL) compared with controls (23.4 ng/mL; P=0.01). However, elevated FABP4 
was associated with adverse secondary cerebrovascular or cardiovascular events during 30-day follow-up after index 
ACS, independent of age, sex, renal function, and body mass index (odds ratio, 1.7; 95% confidence interval, 1.1–2.5; 
P=0.02). Circulating FABP4 predicted adverse events with similar prognostic performance as the GRACE in-hospital 
risk score or N-terminal pro–brain natriuretic peptide. Finally, no significant difference between baseline FABP4 was 
found in asymptomatic individuals with or without coronary events during 5-year follow-up.
Conclusions—Circulating FABP4 may prove useful as a prognostic biomarker in risk stratification of patients with 
ACS.  (Arterioscler Thromb Vasc Biol. 2015;35:1872-1879. DOI: 10.1161/ATVBAHA.115.305365.)
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healthy tissue. The few differentially expressed transcripts and 
proteins identified by both approaches included fatty acid–
binding protein 4 (FABP4). Its expression in atherosclerotic 
plaques of carotid arteries was previously found to predict 
cardiovascular outcome7 or naturally occurring genetic low-
expression variant of FABP4 to promote plaque stability and 
to reduce the risk of cardiovascular events.8
We therefore selected FABP4 for clinical validation as 
a circulating biomarker and considered 3 different situa-
tions, where a novel cardiovascular biomarker may improve 
clinical management of coronary artery disease (CAD). In 
clinical routine, electrocardiography and cardiac troponins 
are the gold standards for making the diagnosis of ACS.9 As 
the trade-off of their high sensitivity, novel cardiac troponin 
assays have reduced specificity,10 what may be improved by 
the determination of additional biomarkers reflecting plaque 
rupture. For this reason, we assessed in a cross-sectional 
study (designated as the diagnostic cohort) diagnostic per-
formance of FABP4 by comparing circulating FABP4 lev-
els of healthy individuals with those of patients with stable 
CAD or ACS. Another medical need is an improvement of 
risk prediction toward optimized or personalized targeting 
of preventive measures. Clinical risk prediction algorithms 
combining demographic, clinical, and biochemical measures 
are nowadays reference methods; however, they differ con-
siderably in primary and secondary prevention settings. For 
instance, for primary prevention in an asymptomatic popu-
lation, algorithms and scores, such as Framingham, Pooled 
Cohort Equations, or European Atherosclerosis Society/
European Society of Cardiology score combine information 
on age and sex with risk factors, such as diabetes mellitus, 
blood pressure, and plasma lipids.11 For secondary preven-
tion of symptomatic patients, the GRACE or thrombolysis in 
myocardial infarction scores combine data on age, cardiovas-
cular, and renal function.12 In our study, we assessed the per-
formance of circulating FABP4 as a prognostic biomarker for 
the incidence of cerebrovascular and cardiovascular events 
in 2 nested case–control studies: 1 with 5-year follow-up of 
asymptomatic individuals from the general population (des-
ignated as prospective population cohort) and another with 
30-day follow-up of patients with ACS (designated as pro-
spective clinical cohort).
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Identification of FABP4 as a Biomarker Candidate
Data sets from 2 independent approaches were combined to 
identify biomarker candidates for CAD. In the first approach, 
using gene array technology, mRNA expression levels iso-
lated from coronary thrombi were compared with those of 
peripheral blood mononuclear cells from patients with ACS. 
In the second approach, protein profiles of atherosclerotic 
plaque–derived secretomes were compared with those of 
Nonstandard Abbreviations and Acronyms
ACS acute coronary syndrome
AUC area under the curve
BMI body mass index
CAD coronary artery disease
CI confidence interval
FABP4 fatty acid-binding protein 4
NT-proBNP N-terminal pro–brain natriuretic peptide
OR odds ratio
STEMI ST-segment–elevation myocardial infarction
Table 1.  Characteristics of the Diagnostic Cohort
Characteristics Controls, n=313 CAD, n=68 NSTEMI, n=170 STEMI, n=269 P Value
Age, y 60±10 62±7 64±13 63±12 <0.001
Sex, male* 214 (68%) 59 (87%) 137 (81%) 207 (77%) 0.001
Hypertension* 159 (51%) 61 (90%) 136 (80%) 184 (68%) <0.001
Hypercholesterolemia* 155 (50%) 58 (85%) 124 (73%) 179 (67%) <0.001
T2DM* 38 (12%) 22 (32%) 52 (31%) 152 (57%) <0.001
Current smoking* 103 (33%) 9 (13%) 73 (43%) 109 (41%) <0.001
Body mass index, kg/m2 27±4 29±5 27±4 27±5 0.034
Total cholesterol, mmol/L 5.8±1.0 4.1±1.1 4.9±1.2 5.1±1.2 <0.001
HDL, mmol/L 1.6±0.4 1.1±0.4 1.1±0.4 1.2±0.3 <0.001
LDL, mmol/L 3.6±0.9 2.3±0.8 3.1±1.1 3.4±1.6 <0.001
Triglycerides, mmol/L† 1.3 (0.6–3.0) 1.0 (0.5–4.4) 1.3 (0.5–3.5) 0.9 (0.4–2.6) <0.001
CRP, mg/L† 1.5 (0.3–8.3) 0.9 (0.3–15.0) 3.6 (0.5–43.5) 2.2 (0.4–35.7) <0.001
hsTnT, µg/L† n.d. n.d. 0.47 (0.015–3.06) 0.22 (0.12–3.34) 0.002
Glucose, mmol/L† 5.6 (4.6–8.1) 5.6 (4.3–11.2) 6.0 (4.6–11.7) 7.4 (5.2–17.2) <0.001
FABP4, ng/mL† 23.4 (5.9–71.0) 22.5 (7.4–73.7) 20.3 (8.8–70.2) 24.9 (10.0–77.9) 0.029
CAD indicates coronary artery disease; CRP, C-reactive protein; FABP4, fatty acid–binding protein 4; HDL, high-density 
lipoprotein; hsTnT, high-sensitive troponin T; LDL, low-density lipoprotein; NSTEMI, non–ST-segment–elevation myocardial 
infarction; NT-proBNP, N-terminal pro–brain natriuretic peptide; STEMI, ST-segment–elevation myocardial infarction; and T2DM, 
diabetes mellitus type 2.
*n (%), χ2 test.
†Median (5th–95th percentile), Mann–Whitney U test.
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healthy tissue secretomes from the corresponding endarter-
ectomized carotid arteries.13 Comparison of 325 upregulated 
mRNAs from coronary thrombi with 390 proteins from the 
secretomes (Table I in the online-only Data Supplement) 
yielded 8 common hits. The FABP4 was the only protein 
detected in the plaque secretomes, but not in the control 
secretomes, its mRNA expression in coronary thrombi was 
55-fold higher than in peripheral blood mononuclear cells 
(Table II in the online-only Data Supplement). Moreover, 
increased FABP4 expression in atherosclerotic plaques of 
carotid arteries was found to predict forthcoming adverse 
cardiovascular events.7 Therefore, FABP4 was selected for 
clinical validation.
FABP4 Confounding Factors and Correlation 
With Other Diagnostic Parameters
In both the diagnostic and the prospective population cohort, 
bivariate analysis revealed weak to moderately positive cor-
relations of circulating FABP4 with age, body mass index 
(BMI), glucose, and C-reactive protein. Notably, FABP4 in 
the diagnostic cohort showed stronger correlation with BMI in 
asymptomatic controls than in CAD patients (P=0.34 versus 
0.22, both P value <0.001). There was no significant corre-
lation of FABP4 with total cholesterol, high-density lipopro-
tein, low-density lipoprotein, or triglycerides in either cohort 
(Table III in the online-only Data Supplement). In general, 
circulating FABP4 levels were significantly higher in women, 
in individuals with BMI >25 kg/m2, diabetes mellitus, or 
with hypertension when compared with men, normal weight, 
nondiabetic, and normotensive counterparts. Circulating 
FABP4 was lower in current smokers than in nonsmokers, but 
this difference was only significant in the diagnostic cohort 
(Table IV in the online-only Data Supplement).
Furthermore, circulating FABP4 showed a very weak pos-
itive correlation with high-sensitive troponin T (P=0.19 and 
0.01) or C-reactive protein (P=0.16 and 0.04) in the diagnostic 
cohort. In the prospective clinical cohort, circulating FABP4 
moderately correlated with the GRACE risk score for in-
hospital death or myocardial infarction (P=0.41 and <0.001), 
with N-terminal pro–brain natriuretic peptide (NT-proBNP; 
P=0.35 and <0.001) and with creatinine (P=0.45 and <0.001; 
Table V in the Data Supplement).
Circulating FABP4 Levels Do Not Differ 
Remarkably Between Patients With 
ACS and Asymptomatic Controls
The cross-sectional diagnostic cohort included 820 indi-
viduals from both SPUM-ACS (Special Program University 
Medicine-Acute Coronary Syndrome; n=553) and CoLaus 
(Cohorte Lausannoise; n=267) studies. The SPUM-ACS par-
ticipants were recruited at the University Hospital Zurich and 
included 46 healthy controls, 68 patients with stable CAD, 
269 patients with ST-segment–elevation myocardial infarc-
tion (STEMI), and 170 patients with non–ST-segment–ele-
vation myocardial infarction. Since the number of healthy 
controls was low in the SPUM-ACS study and these individu-
als were younger than patients with CAD (data not shown), 
additional controls were selected from the CoLaus study 
Figure 1. Odds ratios (ORs) for associations of risk factors and circulating fatty acid–binding protein 4 (FABP4) with different clinical 
manifestations of acute coronary syndrome in the diagnostic cohort. Multivariate logistic regression models with adjustment for several 
confounding factors, such as sex (male), age (years), BMI (body mass index; kg/m2), hypertension, or diabetes mellitus, were used. Plots 
show odds ratios with corresponding 95% confidence intervals (CIs) and P values for the 1-SD changes in the log-transformed FAPB4, 
and 1-SD changes in the age and BMI (Wald statistics). Models for controls vs ST-segment–elevation myocardial infarction (STEMI; A and 
B) and non–STEMI vs STEMI (C and D). The vertical reference line indicates an OR of 1.0. T2DM indicates diabetes mellitus type 2.
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cohort. Detailed clinical and laboratory characteristics are 
shown in Table 1.
One-factorial ANOVA with Games–Howell correction 
was applied for multiple comparisons of circulating FABP4 
in asymptomatic controls, patients with stable CAD and 
patients with ACS, respectively. Circulating FABP4 was sig-
nificantly higher (P=0.01) in patients with STEMI (median 
24.9 ng/mL with 5th–95th percentile range, 11.0–77.9) com-
pared with asymptomatic controls (median 23.4 ng/mL with 
5th–95th percentile range, 5.9–71.0). Other groups did not 
differ significantly from each other with respect to the circu-
lating FABP4.
The difference in the circulating FABP4 between 
patients with STEMI and asymptomatic controls remained 
significant after adjustment for age, sex, and BMI (odds 
ratio [OR], 1.3; 95% confidence interval [CI], 1.1–1.6; 
P=0.004). However, this significance was lost after further 
adjustment for diabetes mellitus and hypertension (OR, 
1.2; 95% CI, 1.0–1.5; P=0.1). In contrary, differences in 
the circulating FABP4 between patients with STEMI and 
non–ST-segment–elevation myocardial infarction became 
statistically significant in both adjusted models (OR, 1.4; 
95% CI, 1.1–1.8; P=0.003 and OR, 1.4; 95% CI, 1.1–1.8; 
P=0.01). The details of logistic regression models are pre-
sented in Figure 1. No other differences in the circulating 
FABP4 became statistically significant after adjustment for 
the confounding factors.
Circulating FABP4 Predicts the Occurrence of 
Adverse Cerebrovascular and Cardiovascular 
Events in Patients With ACS
The prognostic performance of circulating FABP4 for future 
cerebrovascular or cardiovascular events was assessed in a 
nested case–control study of 200 patients with ACS from 4 
hospitals participating in the SPUM-ACS study. These patients 
had a primary diagnosis of unstable angina (n=12), STEMI 
(n=106), or non–ST-segment–elevation myocardial infarc-
tion (n=82). During 30-day follow-up, 70 patients developed 
adjudicated cerebrovascular and cardiovascular events: death 
(34 cardiac deaths and 3 unclear deaths), recurrent myocardial 
infarction (n=22), or stroke (n=11). Cases were matched for 
age, sex, and center with 130 patients who survived 30 days 
without any event (Table 2).
Circulating FABP4 was significantly higher in patients 
who developed adverse cerebrovascular and cardiovas-
cular events during the follow-up compared with control 
patients without any event: 39.9 ng/mL (5th–95th percentile 
range, 15.0–307.7) versus 26.4 ng/mL (5th–95th percentile 
range, 13.8–97.9), respectively, P=0.001. These differences 
remained statistically significant after adjustment for age, sex, 
creatinine level, and BMI (OR, 1.7; 95% CI, 1.1–2.5; P=0.02; 
Figure 2).
The prognostic performance of FABP4 for predicting 
adverse cerebrovascular or cardiovascular events during 
the follow-up was further assessed by comparison with the 
Table 2. Matching for Controls and Cases in the Prospective Clinical Cohort of Patients With 
Acute Coronary Syndrome During 30-d Follow-Up (n=200)
Characteristic Controls, n=130 Cases, n=70 P Value
Clinical presentation*
  UA 8 (6%) 4 (6%) 0.20
  NSTEMI 59 (45%) 23 (33%)
  STEMI 63 (49%) 43 (61%)
Age, y 71±12 72±11 0.71
Sex, male* 91 (70%) 50 (71%) 0.83
Hypertension* 95 (73%) 46 (66%) 0.28
T2DM* 24 (18.5%) 21 (30%) 0.06
Current smoking* 31 (24%) 23 (33%) 0.13
BMI, kg/m2 27±4 27±5 0.26
Total cholesterol, mmol/L 4.7±1.3 4.5±1.2 0.38
HDL, mmol/L 1.2±0.4 1.2±0.3 0.59
LDL, mmol/L 2.9±1.2 2.8±1.0 0.93
Triglycerides, mmol/L 1.3±0.8 1.1±0.7 0.11
CRP, mg/L† 2.9 (0.5–73.5) 5.8 (0.4–97.9) 0.04
hsTnT, µg/L† 0.306 (0.012–3.008) 0.743 (0.018–5.323) 0.01
NT-proBNP, ng/L† 797 (43–7314) 1340 (76–28 094) 0.01
Creatinine, µmol/L† 77.0 (52.5–142.7) 88.5 (56.2–202.7) 0.001
FABP4, ng/mL† 26.4 (13.8–97.9) 39.9 (15.0–307.7) 0.001
In-hospital death or myocardial 
infarction GRACE score
212±50 248±68 <0.001
BMI indicates body mass index; CRP, C-reactive protein; FABP4, fatty acid–binding protein 4; HDL, high-density 
lipoprotein; hsTnT, high-sensitive troponin T; LDL, low-density lipoprotein; NSTEMI, non–ST-segment–elevation 
myocardial infarction; NT-proBNP, N-terminal pro–brain natriuretic peptide; STEMI, ST-segment–elevation myocardial 
infarction; T2DM, diabetes mellitus type 2; and US, unstable angina.
*n (%), χ2 test.
†Median (5th–95th percentile), Mann–Whitney U test.
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GRACE risk score (predictor for in-hospital death or myocar-
dial infarction) and NT-proBNP levels. On Cox proportional 
hazard analysis, FABP4 (hazard ratio, 1.40; 95% CI, 1.04–
1.87; P=0.026), GRACE risk score (hazard ratio, 1.44; 95% 
CI, 1.08–1.92; P=0.014), and NT-proBNP (hazard ratio, 1.35; 
95% CI, 1.02–1.81; P=0.039) almost equally contributed to 
the prediction of adverse events during the 30-day follow-up. 
The receiver operating characteristic analysis of FABP4 as a 
prognostic marker revealed an area under the curve (AUC) of 
0.65 (95% CI, 0.56–0.75; P=0.001), which was nearly identi-
cal to that obtained for the GRACE risk score (AUC, 0.67; 
95% CI, 0.57–0.76; P<0.001). The combination of FABP4 
and GRACE scores did not further improve the prediction 
of the outcome (AUC, 0.67; 95% CI, 0.57–0.76; P<0.001). 
The AUC for NT-proBNP (AUC, 0.61; 95% CI, 0.53–0.71; 
P=0.045) was lower, but the combination of FABP4 and 
NT-proBNP reached the highest AUC of 0.68 (95% CI, 0.60–
0.77; P=0.045; Figure 3).
Circulating FABP4 at Baseline Does Not 
Predict the Development of Cardiovascular 
Events in the Asymptomatic Population
The prognostic performance of circulating FABP4 for future 
cardiovascular events was assessed in the prospective nested 
case–control cohort of 414 asymptomatic participants from 
the population-based CoLaus study. During 5-year follow-
up, 112 individuals experienced an adjudicated cardiovascu-
lar event: 22 cardiovascular deaths, 54 myocardial infarction, 
and 36 symptomatic CAD followed by percutaneous or surgi-
cal revascularization. These cases were matched by sex, age, 
and health status with 302 controls who did not manifest any 
CAD event (Table 3). No significant difference in circulating 
FABP4 was found between individuals with or without inci-
dence of cardiovascular event: 23.7 ng/mL (5th–95th percen-
tile range, 5.9–76.8) versus 23.3 ng/mL (5th–95th percentile 
range, 9.3–71.4), P=0.75.
Discussion
The purpose of this project was the identification of novel 
CAD biomarkers by integration of proteomic and gene 
expression profiling data sets obtained from atherosclerotic 
plaque secretomes and coronary thrombi, respectively. The 
proteomic study aimed for the identification of proteins that 
are released from the plaque into the circulation during the 
progression or rupturing of atherosclerotic plaque. We previ-
ously showed that the composition and phenotype of mono-
nuclear cells in coronary thrombi differ significantly from 
Figure 2. Odds ratios (ORs) for associations of confounding 
factors and circulating fatty acid–binding protein 4 (FABP4) in 
patients with adverse cerebrovascular and cardiovascular events 
during 30-day follow-up after the index acute coronary syndrome 
event. Multivariate logistic regression model with adjustment for 
several confounding factors, such as sex (male), age (years), BMI 
(body mass index; kg/m2), and creatinine (μmol/L) were used. Plot 
shows ORs with corresponding 95% confidence intervals (CIs) 
and P values for the 1-SD changes in the log-transformed FAPB4 
and creatinine values, and 1-SD changes in the age and BMI 
(Wald statistics). The vertical reference line indicates an OR of 1.0.
Figure 3. Fatty acid–binding protein 4 (FABP4) predicts adverse cerebrovascular and cardiovascular events during 30-day follow-up after 
an index acute coronary syndrome event. A, The calculated areas under the curve (AUCs) for FABP4, GRACE risk score, and their com-
bination as predictors of adverse events was 0.65 (95% confidence interval [CI], 0.56–0.75; P=0.001), 0.67 (95% CI, 0.57–0.76; P<0.001), 
and 0.67 (95% CI, 0.57–0.76; P<0.001), respectively. B, The calculated AUCs for N-terminal pro–brain natriuretic peptide (NT-proBNP) 
was 0.61 (95% CI, 0.53–0.71; P=0.045) and for the combination of FABP4 and NT-proBNP was 0.68 (95% CI 0.60–0.77, P=0.045).
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those of peripheral blood mononuclear cells obtained from 
patients with ACS.14,15 Therefore, differential gene expres-
sion profiling was performed to identify molecular charac-
teristics of thrombus-associated mononuclear cells that could 
also serve as ACS biomarkers. Comparison of both data sets 
revealed several common targets. One of them, FABP4 (also 
known as AFABP or aP2) was found in the plaque secretome 
but not in the control secretome and its expression in coro-
nary thrombi was 55-fold higher than in peripheral blood 
mononuclear cells.
FABP4 is abundantly produced in adipocytes, but sig-
nificant amounts of FABP4 are also found in macrophages, 
which are pathogenic constituents of atherosclerotic 
plaques. Furthermore, a naturally occurring genetic low-
expression variant of FABP4 was found to promote plaque 
stability and reduce the risk of cardiovascular events.8 On 
the contrary, FABP4 expression is increased in vulnerable 
and ruptured plaques as shown by genome-wide expression 
analysis of isolated macrophages16 and quantification of 
FABP4 in vulnerable human plaques.7 Extensive studies in 
FABP4-deficient mice or FABP4 inhibitor–treated animals 
also demonstrated that FABP4 promotes insulin resistance 
and the development of diabetes mellitus and modulates 
lipid metabolism.17 Moreover, FABP4 seems to play an 
important role in the development of atherosclerosis. For 
instance, in the absence of any significant differences in 
serum lipids and insulin sensitivity, FABP4/ApoE-double–
knockout mice developed markedly less atherosclerosis than 
control ApoE-knockout mice. Interestingly, the reduction of 
atherosclerotic lesions was similar in macrophage-specific 
FABP4 deficiency and whole-body FABP4-deficient mice.18 
These data indicate that macrophage-derived FABP4 may 
exert local pathogenic effects in atherosclerosis indepen-
dent from its established role in systemic glucose or lipid 
metabolism.
Therefore, we selected FABP4 for further validation as a 
diagnostic and prognostic biomarker for atherosclerotic CAD. 
Our validation studies confer 3 major findings on circulating 
FABP4 as a diagnostic and prognostic biomarker.
Firstly, circulating FABP4 was not associated in a clini-
cally meaningful manner with the presence of stable CAD 
or its acute manifestations. In line with our results, Cabré et 
al19 demonstrated that circulating FABP4 levels are not sig-
nificantly associated with clinical or subclinical atheroscle-
rosis but are markedly increased in patients with metabolic 
syndrome. In contrast to the studies in whites, several stud-
ies in Asian populations showed significant associations 
of circulating FABP4 with CAD. For instance, circulating 
FABP4 correlated positively with carotid intima-media 
thickness in Chinese women,20 with atherosclerotic bur-
den measured by intravascular ultrasound,21 or with CAD 
in nonelderly Japanese men.22 These discrepant findings 
between white and Asian populations on the association of 
circulating FABP4 with CAD might be partially explained 
by different genetic and environmental background. For 
instance, the prevalence of hypertension, hypercholesterol-
emia, or overweight and obesity is higher in whites than 
in Asians.23,24 It has to be noted that these conditions are 
associated with higher FABP4 levels, as found in this and 
other studies.25,26
Secondly, circulating FABP4 was significantly elevated 
in patients with ACS who experienced adverse cerebrovas-
cular or cardiovascular events within 30 days after the index 
ACS event. Furthermore, FABP4 showed the same prognostic 
power to predict adverse events as the GRACE in-hospital risk 
score or NT-proBNP. Although the highest concentration of 
FABP4 was observed in patients with ACS who experienced 
cardiac death (data not shown), our nested cohort is too small 
to claim a differential prognostic role of FABP4 in the pre-
diction of fatal and nonfatal events. It is interesting to note 
that a significant association of FABP4 with cerebrovascular 
or cardiovascular events was also observed in a prospective 
10-year long follow-up study of patients with CAD.27 In this 
study, high baseline levels of FABP4 were associated with a 
higher risk for subsequent adverse events in unadjusted analy-
ses and significantly predicted cardiovascular death even after 
adjustment for established cardiovascular risk factors and 
lipid-lowering drugs.
Finally, circulating FABP4 had no association with inci-
dence of cardiovascular events in our prospective population 
cohort. In a similar study of Hong Kong Chinese, circulating 
FABP4 was found to predict the development of CAD after 
adjustment for the traditional risk factors. Despite indepen-
dent association with an integrated discrimination improve-
ment of 0.25%, FABP4 helped only marginally to improve 
the performance of the predictive model with established risk 
factors.28
The following limitations of our study have to be consid-
ered. Our data do not imply any causal relationship between 
circulating FABP4 and development of adverse events after 
Table 3. Matching Controls and Cases in the Prospective 
Population Cohort During 5-y Follow-Up (n=414)
Variable Controls, n=302 Cases, n=112 P Value
Age, y 60.9±9.8 61.2±9.4 0.77
Sex, men* 208 (69%) 81 (70%) 0.50
Hypertension* 185 (61%) 70 (63%) 0.82
T2DM* 43 (14%) 21 (19%) 0.26
Current smoking* 118 (39%) 41 (37%) 0.65
BMI, kg/m2 27.9±4.6 28.4±5.4 0.38
Total cholesterol, mmol/L 5.8±1.1 5.7±1.0 0.18
HDL, mmol/L 1.5±0.4 1.4±0.4 0.03
LDL, mmol/L 3.6±1.0 3.5±0.9 0.23
Triglycerides, mmol/L 1.6±0.8 1.7±0.9 0.10
hsCRP, mg/L† 1.7 (0.4–10.5) 2.3 (0.3–17.3) 0.04
FABP4, ng/mL† 23.7 (5.9–76.8) 23.3 (9.3–71.4) 0.75
BMI indicates body mass index; FABP4, fatty acid–binding protein 4; HDL, 
high-density lipoprotein; hsCRP, high-sensitive C-reactive protein; LDL, low-
density lipoprotein; and T2DM, diabetes mellitus type 2.
*n (%), χ2 test.
†Median (5th–95th percentile), Mann–Whitney U test.
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the index ACS. The sample size of our prospective clinical 
cohort was rather modest, and additional studies with larger 
numbers are required to confirm our findings and to validate 
the prognostic performance of FABP4.
In conclusion, circulating FABP4 was associated with 
neither stable CAD nor ACS, and thus is unlikely to serve 
as a clinically relevant diagnostic biomarker. Neither does it 
seem to be a relevant predictive biomarker in an asymptomatic 
population. However, in patients with ACS, FABP4 may serve 
as a prognostic marker to identify patients at risk for adverse 
cerebrovascular or cardiovascular events.
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